Latest Announcements

Investor Announcement, Huntington's Disease

PBT2 recommended for orphan designation in Europe

Prana Biotechnology is pleased to announce the European Medicines Agency’s Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending designation of PBT2 for the treatment of Huntington disease as an orphan medicinal product to the European Commission (EC).


Investor Announcement, Clinical Trials

FDA End of Phase 2 Status Update

Prana Biotechnology has today announced the status of its End of Phase 2 discussions with the US Food and Drug Administration (FDA).


Movement disorders expert Professor Ira Shoulson joins Prana Biotechnology's Board of Directors

Email Newsletter

Receive regular updates from Prana Biotechnology by entering your details below and clicking "Subscribe"